AIM ImmunoTech Inc.

Regulatory Filings • Jul 24, 2025

CORRESP 1 filename1.htm

July 24, 2025

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-1004

Re:
Registration Statement on Form S-1, as amended
File No. 333-284443

Ladies and Gentlemen:

As the placement agent of the proposed offering of AIM ImmunoTech Inc. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 5:00 p.m., Eastern Time, on Monday, July 28, 2025, or as soon thereafter as is practicable.

Pursuant to Rule 460 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, we wish to advise you that, through July 24, 2025, we distributed to each dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies, as well as “E-red” copies of the Preliminary Prospectus dated July 22, 2025, as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Very truly yours,
Maxim Group LLC
By:	/s/
Ritesh Veera
Name:	Ritesh
Veera
Title:	Co-Head
of Investment Banking

Field: Page; Sequence: 1; Options: Last

Field: /Page